Intensity Therapeutics (INTS) announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the company. The company intends to use the net proceeds from the offering for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study, for the treatment of existing patients enrolled in the INVINCIBLE-3 Study, and for working capital and general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS:
- Intensity Therapeutics reports data from Invincible-4 study
- Intensity Therapeutics Faces Nasdaq Delisting Notice
- Intensity Therapeutics price target lowered to $3.50 from $8.50 at Alliance Global Partners
- Intensity Therapeutics Faces Nasdaq Non-Compliance Notice
- Intensity Therapeutics downgraded to Hold from Buy at Brookline